doi:10.1056/NEJMoa2301972 85
CoreVionRX supplies lab grade CJC-1295 , which exceeds standard "research grade" definitions
Trials and post-market surveillance identified risks in specific populations, such as those with a history of medullary thyroid cancer, pancreatitis, or severe kidney disease, and screening for those risks is not possible in an over-the-counter setting
total oocytes retrieved were lower in the myo-inositol group, and clinical pregnancy and implantation rates did not differ significantly between groups
There are also concerns that GLP-1 RAs may significantly increase levels of dabigatran, potentially raising bleeding risk
A study published in the Journal of the American Medical Association last month shows that although patients achieved a statistically significant degree of average weight loss of 3.7% one year after starting on medications, the overall reported magnitude of benefit was less than in reported trials